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Abstract
Fluoropyrimidines, including 5-fluororacil (5FU) and its pro-drug Capecitabine, are the com-
mon treatment for colorectal, breast, neck and head cancers—either as monotherapy or in
combination therapy. Adverse reactions (ADRs) to the treatment are common and often
result in treatment discontinuation or dose reduction. Factors contributing to ADRs, includ-
ing genetic variation, are poorly characterized. We performed exome array analysis to iden-
tify genetic variants that contribute to adverse reactions. Our final dataset consisted of 504
European ancestry individuals undergoing fluoropyrimidine-based therapy for gastrointesti-
nal cancer. A subset of 254 of these were treated with Capecitabine. All individuals were
genotyped on the Illumina HumanExome Array. Firstly, we performed SNP and gene-level
analyses of protein-altering variants on the array to identify novel associations the following
ADRs, which were grouped into four phenotypes based on symptoms of diarrhea, mucositis,
and neutropenia and hand-and-foot syndrome. Secondly, we performed detailed analyses
of the HLA region on the same phenotypes after imputing the HLA alleles and amino acids.
No protein-altering variants, or sets of protein-altering variants collapsed into genes, were
associated with the main outcomes after Bonferroni correction. We found evidence that the
HLA region was enriched for associations with Hand-and-Foot syndrome (p = 0.023), but no
specific SNPs or HLA alleles were significant after Bonferroni correction. Larger studies will
be required to characterize the genetic contribution to ADRs to 5FU. Future studies that
focus on the HLA region are likely to be fruitful.
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Introduction
Fluoropyrimidines, including 5-fluororacil (5FU) and its pro-drug Capecitabine, are the com-
mon treatment for colorectal, breast, neck and head cancers—either as monotherapy or in
combination therapy. Adverse reactions (ADRs) to the treatment are common and dose
reduction or treatment discontinuation due to toxicity are often necessary.[1] Severe toxicity
can have a rapid onset and may result in mortality in a small proportion (0.5–2%) of patients.
[2, 3] Common symptoms of toxicity include diarrhea, mucositis, and neutropenia; as well as a
distinctive dermatological toxic reaction known as hand-and-foot syndrome (HFS).[4] Some
degree of HFS is common (50–60%) in patients treated with the fluoropyrimidine pro-drug
Capecitabine, but severe reactions are more rare, occurring in 10–17% of individuals.[4]
Factors contributing to ADRs to 5FU are not well characterized. Inter-individual genetic
variation is likely to contribute significantly. Variants in the dihydropyrimidine dehydroge-
nase (DPYD) gene, which encodes the primary enzyme required to metabolise fluororacil, con-
tribute to risk of toxicity.[5, 6] However, these variants are rare, explaining only a proportion
of risk, and therefore other contributing factors are likely to exist. Indeed, other associated var-
iants have been identified using a candidate gene approach—including variants in TYMS and
MTHFR.[7–9] However, the clinical relevance of these variants remains uncertain.[10] A
genome-wide study of toxicity has been reported, but none of the identified associations have
since been validated. [11] Genetic associations specifically with HFS have also been reported,
[8, 12, 13] but large well-powered genetic studies of HFS are largely absent from the literature.
Many of the associations to date have been identified using a candidate gene approach,
which has been shown to have poor reproducibility.[14] Indeed, the candidate gene approach
has in general been superseded by agnostic whole-genome or whole-exome approaches, which
survey the entirety of the genome or exome for associations. In this analysis, we use exome
array technology to perform two analyses. First, we carry out a comprehensive assessment of
the influence of protein altering variation at the SNP and gene level on ADRs to 5FU. Sec-
ondly, given the importance of the Human Leukocyte Antigen (HLA) in immune response
and its prior association with drug responses,[15] we perform detailed assessment of the influ-
ence of genetic variation in the HLA on 5FU ADRs.
Methods
Patients and clinical data
Patient data was derived from two populations. The first was based on a series of 430 patients
recruited from oncology clinics, and treated with 5FU or Capecitabine, forming part of a
regional cancer network in South East London, UK; and described in detail previously. [8]
Ethical approval was obtained from St Thomas’ Hospital Research Ethics Committee (07/
H0802/143) and written consent was provided by all patients. For inclusion in the study,
patients had to fulfil the following criteria: (1) World Health Organisation performance status
<2; (2) life expectancy greater than or equal to 3 months; (3) any previous chemotherapy
completed greater than or equal to 6 months ago; and (4) adequate haematological and cardiac
status. Although the study was retrospective, clinical outcome data were obtained from stan-
dardised oncology outcome records completed at each clinic visit. Pre-treatment evaluation
included a complete physical examination and recording of the following information: (1)
baseline patient demographics (age, sex and ethnicity) and medical history; (2) diagnosis of
tumour and staging (tumour, node, metastasis system); (3) current chemotherapy regimen
(drug, dosing regimen) and (4) baseline blood analyses. Patients were assessed for treatment
tolerance and had full blood count, renal function and liver function monitored before each
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chemotherapy cycle. All chemotherapy related toxicity in the first four cycles of treatment was
recorded according to the National Cancer Institute Common Toxicity Criteria version 3.
Patient outcome data were not disclosed to investigators undertaking the genetic analysis.
The second population consisted of 359 patients who, in addition to treatment with Capeci-
tabine or 5-FU, had received oxaliplatin-based chemotherapy for the treatment of colorectal
tumours. They were recruited from oncology outpatient clinics at Guy’s and St. Thomas’ NHS
Hospital Trust, with the majority of patients (>98%) receiving treatment for colorectal carci-
noma. Individuals were excluded from this analysis if this was not their first-line Capecitabine
or 5FU treatment or if they had undergone previous 35 or 42 day Capecitabine cycles.
Phenotype classification
Association was tested for two measured toxicity outcomes. Diarrhoea, mucositis and neutro-
penia (DMN) in the first four cycles of treatment were dichotomised as either mild to moder-
ate (grade 0–2) or severe (grade 3–4) in all patients. In Capecitabine patients only, the primary
ADR of interest was HFS. No grade 4 HFS was reported in the Capecitabine cohort, so two
analyses were performed: for HFS (grade 0–1 v. grade 2–3) and for severe HFS (grade 0–2 v.
grade 3). In addition we evaluated associations with Diarrhoea and Mucositis (DM), dichoto-
mised as either mild to moderate (grade 0–2) or severe (grade 3–4) in the Capecitabine
subgroup.
Genotyping and quality control
All individuals were genotyped using the Illumina HumanExome v1.1 chip, which includes
247,870 protein-altering variants identified from whole-exome sequencing of>12,000 individ-
uals. The array also features 2,459 HLA tags, 4,761 GWAS trait-associated SNPs, as well as
ancestry-informative markers, identity-by-descent estimation markers and random synony-
mous SNPs to enable construction of principal components of ancestry. Comprehensive
details about the exome array are available at http://genome.sph.umich.edu/wiki/Exome_
Chip_Design.
Quality control (QC) of the cohort of 5FU patients was carried out on a larger dataset of
2,448 individuals, following validated procedures.[16] Manual inspection of SNP cluster plots
was carried out in Genome Studio to preserve rare variants within the data. Initial call rate,
gender mismatch, and visual cluster checks were also made. The SNPs were then called using
zCall.[17] The above steps were applied separately to two batches (N = 1,798 and N = 650) and
then merged together for further QC. SNPs were retained provided they had a call rate of 0.99
and HWE p-value >1x10-6. Individuals were retained provided their SNP call rate was>0.97,
and any first degree relatives were removed after examining cryptic relatedness. After perform-
ing a sanity check to confirm associations of DPYD variants in the dataset as expected, we
removed any individual who had any copies of four DPYD variants (c.1905+1G>A,
c.2846A>T, c.1601G>A and c.1679T>G) known to be associated with ADRs.[8]
We tested for any batch effects arising from calling SNPs in two stages by (1) comparing
allele frequencies; (2) testing whether loadings on principal components was correlated with
batch to show that sample spreads and population structure are similar. Principal component
(PCs) were calculated using smartpca (EIGENSTRAT) on autosomal variants pruned for link-
age disequilibrium (LD) and with MAF>0.01.[18] This was first performed in combination
with European, African and East Asian samples from the 1000 Genomes project. We then sub-
set our samples on those that segregated with the European reference samples, and then
repeated the principal components analysis until no individual was more than 6 standard
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deviations from the median on the first 5 principal components. All quality control was per-
formed using PLINK v1.90b3.32.[19]
HLA imputation
The Illumina HumanExome Array contains a set of 2,459 SNPs that tag variation across the
HLA. We used these SNPs to impute SNPs, amino acids, and HLA alleles across the region.
Imputation was performed using SNP2HLA,[20] using the Type 1 Diabetes Genetics Consor-
tium (T1DGC) reference panel of 5,225 unrelated individuals. This resulted in imputed data
relating to 728 HLA amino acids, 180 HLA alleles, and 5788 SNP genotypes.
Statistical analysis
To assess the association of genetic variants with adverse reactions to 5FU, we performed two
separate analyses; gene level and SNP level tests. Gene level tests work on the assumption that
multiple variants impacting on the trait under study might reside in the same gene. These tests
therefore test the aggregate impact of variants within a gene region on the trait, which can
have the benefit of addition study power. [21] Conversely, SNP level tests perform a test of
association of the trait with single genetic variants. We interrogated expression of potentially
implicated genes using the GTEx portal (https://www.gtexportal.org/.
Gene level tests
Gene-level tests of association were performed using the Variant Association Tools (VAT)
package.[22] We used the Combined and Multivariate Collapsing (CMC) and Sequence Ker-
nel Association (SKAT) tests to evaluate associations of variants within RefSeq genes, [21, 23]
imposing default weights, filtering on MAF<0.05 and including the first two ancestry-infor-
mative principal components as covariates in all analyses. Analysis was restricted to protein-
altering variants. We set the significance level to p<5x10-6, corresponding to Bonferroni cor-
rection for the approximate 10,000 genes in each analysis.
SNP level tests
Associations of protein-altering SNP genotypes with each of the four ADRs were performed
using PLINK v1.90b3.32, in each case including two ancestry-informative principal compo-
nents to control for population structure. We assessed whether association statistics had the
expected distribution by calculating genomic inflation factors and generating QQ-plots. We
set the significance threshold to p<8.4x10-7 corresponding to Bonferroni correction for the
59,277 variants tested.
To attempt to prioritise sub-threshold associations at the SNP and gene level, we evaluated
whether any of our top associations showed evidence of interaction with proteins in the DPD
pathway. We used the STRING database to identify proteins with interactions with DPYD,
TYMS,DCA,MTHFR, and DPYS with medium confidence, [24] and investigated whether any
of these interacting proteins overlapped with any of our lead associations.
HLA analysis
To interrogate the influence of HLA alleles on ADRs, we performed several analyses, as
follows:
We first assessed the evidence that variation across the entire HLA region contributed
to risk of each ADR. We calculated the sum of chi-squared association statistics for all geno-
typed SNPs across the region for each outcome, obtaining the observed association. We then
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generated 10,000 permutations of the phenotypes, and calculated permuted association values
for each permutation, again summing chi-squared association statistics across the region. We
calculated a p-value by tabulating the number of permutations at which the permuted sum of
chi-squared association statistics equalled or exceed the observed association and dividing by
the number of permutations.
Based on the 6696 imputed HLA alleles, amino acids and genotypes, we performed associa-
tion analysis across the region for each of the four outcomes (DMN, DM, HFS, severe HFS)
using PLINK v1.90b3.32, including two principal components in all analyses. We set the signif-
icance threshold at p<7.5x10-6, corresponding to a Bonferroni correction for all 6696 imputed
elements.
Results
After quality control procedures, our dataset consisted of 504 individuals of European ancestry
(Table 1) for which information was available on 74,224 SNPs, 59,277 of which were protein-
altering variants and 2,283 of which resided in the HLA region.
Gene level tests
We performed CMC and SKAT tests to evaluate whether genetic variation in tested genes con-
tributed to ADRs. No genes in any of the four analyses (DMN, DM, HFS, severe HFS) reached
our predetermined significant threshold (p<5x10-6). The ten most associated genes in each of
the analyses are presented in Tables A-D in S1 File. The strongest association was for the phe-
notype of DMN with Unc-51 Like Kinase 4 (ULK4) using a SKAT test (p = 1.2x10-5). The
strongest association with HFS phenotypes was for Phosphatidylinositol Transfer Protein,
Membrane-Associated 3 (PITPNM3), which is expressed in both the transverse and sigmoid
colon. [25], with severe HFS (CMC, p = 1.7x10-4; SKAT, p = 1.2x10-4).
SNP level tests
Genome-wide association results for genotyped variants are presented in Fig 1. No SNP
reached our significance threshold in this analysis. Genomic inflation was well controlled for
all analyses (λ 1.01; Figure A in S1 File), suggesting no confounding due to population struc-
ture or technical artefact. The strongest associations were for exm462045, in IQ Motif Con-
taining GTPase Activating Protein 2 (IQGAP2), with DM (p = 1.0x10-4); and for exm709846,
in Transmembrane Protein 67 (TMEM67), with severe HFS (p = 3.4x10-5). Both are expressed
in both the transverse and sigmoid colon. [25] The top associations for each of the four out-
comes are presented in Tables 2 and 3.
As IQGAP2 has been implicated in colonic inflammation in mice, [26] we explored whether
its expression was different in patients with Crohn’s Disease compared to controls, using
Table 1. Cohort characteristics.
Affected Unaffected
N % male Age (sd) N % male Age (sd)
DMN 133 58.4 65.0 (11.0) 369 60.7 62.1 (12.1)
DM 50 57.1 66.0 (11.8) 199 60.7 63.3 (11.0)
HFS 36 47.2 64.4 (12.8) 218 62.4 63.8 (10.9)
Severe HFS 13 69.2 64.2 (11.4) 241 60.0 63.8 (11.2)
DM, HFS, Severe HFS considered in Capecitabine subgroup only.
https://doi.org/10.1371/journal.pone.0188911.t001
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Fig 1. Manhattan plots of −log10(p-value) for association of genomewide protein-altering variants with DMN, DM, HFS and severe HFS by
genomic position. HFS, Hand-and-Foot syndrome; DMN, Diarrhoea, mucositis and neutropenia; DM, Diarrhoea and mucositis.
https://doi.org/10.1371/journal.pone.0188911.g001
Table 2. Top protein-altering SNP associations from genome-wide association analysis for ADRs.
rsID CHR BP GENE RA RA Freq OR P-value
DM
exm462045 5 75923294 IQGAP2 A 0.047 4.61 0.00010
exm1084826 14 20872881 TEP1 A 0.20 2.67 0.00014
exm543802 6 38750888 DNAH8 G 0.14 2.77 0.00039
exm1087032 14 21991626 SALL2 C 0.32 2.27 0.00050
exm1476224 19 44117052 SRRM5/ZNF428 A 0.061 3.72 0.00061
exm792722 9 136131651 ABO A 0.082 3.64 0.00071
exm402548 4 69078113 FTLP10/TMPRSS11BNL A 0.22 2.68 0.00075
exm402563 4 69094507 TMPRSS11BNL A 0.22 2.68 0.00075
exm402583 4 69095197 TMPRSS11BNL A 0.22 2.68 0.00075
exm212608 2 96861159 STARD7 G 0.16 2.61 0.00083
DMN
exm1322587 17 39884065 HAP1 A 0.41 0.51 5.5x10-5
exm1084826 14 20872881 TEP1 A 0.20 1.90 0.00017
exm224289 2 121747433 GLI2 A 0.027 4.56 0.00025
exm303483 3 41759288 ULK4 G 0.030 3.97 0.00027
exm1024776 12 85432040 LRRIQ1 A 0.12 0.36 0.00059
exm813014 10 18266989 SLC39A12 G 0.34 0.56 0.00073
exm6576 1 3328659 PRDM16 A 0.13 1.93 0.0011
exm901458 11 43876698 HSD17B12 A 0.29 1.66 0.0014
exm444913 5 13737444 DNAH5 A 0.12 1.96 0.0015
exm598969 7 1595068 TMEM184A A 0.26 1.68 0.0015
CHR, chromosome, BP, base position; RA, reference alleles; RA Freq, Frequency of reference allele; OR, odds ratio; DMN, Diarrhoea, mucositis and neutropenia; DM,
Diarrhoea and mucositis.
https://doi.org/10.1371/journal.pone.0188911.t002
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RNA-seq data derived from the colon in 76 cases and 28 controls. IQGAP2 showed signifi-
cantly decreased expression (log(Fold Change) = -0.25; p = 2.9x10-4), highlighting that this
gene is likely to be important in colonic inflammation.
HLA analysis
Using a permutation-based approach, we found evidence that variation across the entire HLA
region contributes to the risk of HFS (p = 0.023). Conversely, there was no evidence of associa-
tion with severe HFS (p = 0.070), DMN (p = 0.20) or DM (p = 0.44).
When performing association analysis of SNPs, amino acids, and HLA-alleles across the
HLA region, the most significant associations were with HFS in the Class I region (Fig 2). The
strongest association was with rs3093960 (OR(95% CI) = 4.5(2.1–9.5); p = 9.5x10-5) in the
Class I region. However, no associations met the Bonferroni-correction threshold of
p<7.5x10-6.
Discussion
ADRs to fluoropyrimidine-based chemotherapy are a major clinical problem and often neces-
sitate dose reduction or treatment discontinuation. Currently, dosing is based on surface area
alone and does not capture inter-individual differences based on genetics or other factors.
Indeed, grade 3–4 toxicity has been reported in 10–30% of individuals,[2] emphasising that
current dosing strategies are unsatisfactory. Previous candidate gene studies have highlighted
the importance of DPYD variants, [5] [6] while other studies have pointed to associations in
Table 3. Top protein-altering SNP associations from genome-wide association analysis for ADRs.
rsID CHR BP GENE RA RA Freq OR P-value
HFS
exm1183401 15 83428192 FSD2 A 0.18 3.24 9.1x10-5
exm1199144 16 825255 MSLN A 0.041 6.00 0.00031
exm967406 11 124767067 ROBO4 G 0.22 2.94 0.00037
exm1514136 19 58117083 ZNF530 G 0.15 3.17 0.00047
exm1418230 19 8176640 FBN3 A 0.22 2.70 0.00057
exm386871 4 6607046 MAN2B2 G 0.014 9.60 0.00057
exm106093 1 155172725 THBS3 G 0.11 3.17 0.00087
exm1324855 17 40722029 MLX G 0.29 2.44 0.00092
exm1540403 20 36993333 LBP G 0.015 15.39 0.00096
exm427090 4 146653620 C4ORF51 A 0.12 3.01 0.00097
Severe HFS
exm709846 8 94772165 TMEM67 A 0.020 17.0 3.4x10-5
exm1284676 17 6386883 PITPNM3 A 0.016 51.8 0.00012
exm1540403 20 36993333 LBP G 0.015 55.2 0.00024
exm1176020 15 74425505 ISLR2 A 0.019 14.4 0.00029
exm108413 1 156146640 SEMA4A A 0.039 10.4 0.00032
exm106714 1 155290231 FDPS G 0.027 10.2 0.00035
exm1476980 19 44471209 ZNF221 T 0.14 4.36 0.00046
exm400335 4 56325365 CLOCK C 0.066 7.00 0.00050
exm1034106 12 108954862 SART3 G 0.17 5.43 0.00069
exm1121827 14 92460176 TRIP11 G 0.0030 91.5 0.00075
CHR, chromosome, BP, base position; RA, reference alleles; RA Freq, Frequency of reference allele; OR, odds ratio; HFS, Hand-and-Foot syndrome.
https://doi.org/10.1371/journal.pone.0188911.t003
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TYMS,MTHFR, and DCA, which are yet to be fully validated. [8] Attempts to identify novel
associations by survey of genome-wide data has so far been relateively small in scale (N = 221).
[11] Here, we performed analyses using the exome array to identify genetic associations with
ADRs in 430 patients undergoing fluoropyrimidine-based chemotherapy for gastrointestinal
cancer.
In a comprehensive survey of protein-altering variants, we were unable to identify any
novel associations with ADRs. Although none of the variants or genes studied reached the
required significance level, several have functions which could plausibly implicate them in
ADRs. Telomere-associated protein 1 (TEP1) was one of the strongest hits for DMN and DM.
This gene plays an important role in cell survival, interacts with the BLM DNA helicase, which
unwinds DNA, and may therefore have a role in DNA repair. Another interesting candidate is
Semaphorin 4A (SEMA4A), which showed a suggestive association with severe HFS in our
analysis. Semaphorins have been implicated in immune and inflammatory responses across
many immune-mediated diseases, and SEMA4A in particular is important in stimulating
immune response by activating T and B cells.[27] Such mechanisms may play a role in patho-
genesis of HFS.
In addition, we performed a detailed analysis of the HLA region. Although we did not iden-
tify any specific novel associations, our permutation-based analysis across the whole HLA sug-
gested that genetic variation across the region contributes to risk of HFS. Given the critical
importance of the HLA system in immune and inflammatory response, it is very plausible
that variation within the region would contribute to risk of ADRs to 5FU. Our results suggest
that further detailed analysis of the region in a large, well–powered dataset are warranted.
Fig 2. Associations of SNP variants, amino acids, and HLA alleles with HFS, severe HFS, DMN and DM across the MHC region. HFS, Hand-and-
Foot syndrome; DMN, Diarrhoea, neutropenia and mucositis; DM, Diarrhoea and mucositis.
https://doi.org/10.1371/journal.pone.0188911.g002
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Our study has limitations. Patients were derived from two cohorts, which we grouped
together to improve power. We combined patients who had undergone treatment with 5FU or
Capecitabine into a single analysis for the outcome of DMN, although Capecitabine is a pro-
drug for 5FU so one might expect ADRs to be consistent between the two. For HFS, severe
HFS and DM, we considered only the Capecitabine subgroup. Although we aimed to survey
all genome-wide protein altering variants, due to our sample size many rare variants were
monomorphic in our dataset. Of the original 247,870 protein-altering variants, only 59,278
were present in the dataset. Therefore, larger samples will be required to provide a comprehen-
sive survey of all known protein-altering variants. Other variants, in TYMS,DCA and MTHFR,
have been reported to be associated with ADRs. These variants were not available on the
exome array, meaning we were unable to investigate them in this analysis.
Our results emphasise that larger studies will be required to characterize the genetic contri-
bution to ADRs. For affected/unaffected ratios equivalent to those in this study, 740 individu-
als would be required to achieve 80% power to identify variants with OR = 3 and MAF = 0.05.
[28]. Additionally, more versatile statistical methods, such as machine learning, might have the
potential to identify associations within datasets of this type. A collaborative effort that builds
on the analysis presented herein is therefore the strategy most likely to bear fruit in the search
for genetic variants contributing to ADRs to fluoropyrimidine-based therapy.
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